Keyword: Taltz

Two of Eli Lilly's key growth drivers came up short in the first quarter, and execs faced a grilling on what they plan to do about it.

Eli Lilly’s Taltz has followed Novartis rival Cosentyx into all its therapy areas. But this time, Lilly wants to be first.

Novartis’ Cosentyx has beaten out rivals from Eli Lilly and J&J to land a psoriasis nod in China.

Drugmakers used last weekend’s American Association of Dermatology annual meeting to trumpet new psoriasis data they hoped would give them an edge.

Lilly provided a forecast for next year that beat analysts’ expectations—welcome news as blockbuster Cialis faces generic rivals.

What’s a surefire way to get noticed in any field? Beat out a behemoth. And that’s what Eli Lilly’s Taltz has just done in psoriatic arthritis.

Generic competition is weighing on Cialis, but luckily for Lilly, several new drugs are on the upswing, including top performers Trulicity and Taltz.

A couple of drugmakers are celebrating this week after favorable decisions from England’s cost watchdog.

China's inviting top brands from Lilly, Novartis, GSK and more to go for approval based on foreign clinical trial data.

Johnson & Johnson immunology newcomer Tremfya is looking to follow in the footsteps of its big brother Stelara.